Literature DB >> 7640054

Comparison of continuous infusion and bolus administration of ifosfamide in children.

A V Boddy1, S M Yule, R Wyllie, L Price, A D Pearson, J R Idle.   

Abstract

The pharmacological effects of ifosfamide (IFO) are dependent on its metabolism which may vary between different modes of administration. This was studied in 17 patients who received both a continuous infusion (9 g/m2 over 72 h) and repeated bolus administration (3 g/m2 every 24 h for 3 days). Concentrations of IFO and its metabolites were determined in plasma and urine. There was up to 70% less of the dechloroethylated metabolites in plasma following bolus administration compared to continuous infusion. Since dechloroethylation results in the formation of the toxic metabolite chloroacetaldehyde, this difference in metabolism may have an impact on the toxicity of IFO. There were no other consistent differences between the two modes of administration. Auto-induction of IFO metabolism, with an increase in dechloroethylated metabolites, was observed for both modes of administration. In conclusion, apart from dechloroethylation, there is little difference between these two modes of administration. However, during multiple cycles of IFO therapy such differences could have a significant effect.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640054     DOI: 10.1016/0959-8049(95)00090-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 2.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

3.  6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.

Authors:  E C Brain; A Mita; P Soulié; H Errihani; A C Hardy Bessard; M Chaouche; J Alexandre; J P Delord; E Cvitkovic; C Jasmin; J L Misset
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

4.  Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

Authors:  Fei Li; Andrew D Patterson; Constance C Höfer; Kristopher W Krausz; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2010-06-10       Impact factor: 5.858

5.  Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.

Authors:  T Kerbusch; J de Kraker; R A Mathĵt; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.

Authors:  J M Singer; J M Hartley; C Brennan; P W Nicholson; R L Souhami
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  The influence of ifosfamide scheduling on acute nephrotoxicity in children.

Authors:  M W English; R Skinner; A D Pearson; L Price; R Wyllie; A W Craft
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.

Authors:  I Willits; L Price; A Parry; M J Tilby; D Ford; S Cholerton; A D J Pearson; A V Boddy
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.